| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8447051 | European Journal of Cancer | 2011 | 9 Pages |
Abstract
Final overall survival analysis of the GBG-26 study did not demonstrate a significant survival benefit for treatment beyond progression with trastuzumab. However, in a post-hoc analysis, patients receiving anti-HER2 treatment as 3rd line therapy showed a better post-progression survival than those not receiving this targeted treatment.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Gunter von Minckwitz, Kathrin Schwedler, Marcus Schmidt, Jana Barinoff, Christoph Mundhenke, Tanja Cufer, Eduard Maartense, Felix E. de Jongh, Klaus H. Baumann, Joachim Bischoff, Nadia Harbeck, Hans-Joachim Lück, Nicolai Maass, Christoph Zielinski,